Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849664 | 0.86 | NOD2 (0.53) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL3993116 | 0.85 | GPR84 (0.49) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL4001760 | 0.85 | SRC (0.53) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL3993302 | 0.84 | GPR84 (0.53) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL27514167 | 0.83 | GPR84 (0.61) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL1850845 | 0.83 | NOD2 (0.51) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL31262896 | 0.82 | GPR84 (0.49) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL29885154 | 0.82 | GPR84 (0.59) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL368690 | 0.82 | GPR84 (0.59) | GPR84FFAR1NOD2HTR2AHTR2C | |
| SCHEMBL1852620 | 0.81 | HTR2A (0.45) | GPR84FFAR1NOD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254081-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2024-08-01 | — | — | US | disclosed |
| EP-4334285-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | Kare Chemical Technologies Inc. (CA) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597329-A | Method for the catalytic synthesis of tryptamine and precursors thereof | 凯尔化学科技公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254081-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | HNMT, TPSB2, TPSG1 | GPR84 1588/4885FFAR1 3614/4885NOD2 2853/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | GPR84 2236/4885FFAR1 2321/4885NOD2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.